- Report
- May 2026
- 355 Pages
Global
From €5266EUR$6,076USD£4,350GBP
- Report
- May 2026
- 241 Pages
Global
From €5266EUR$6,076USD£4,350GBP
- Report
- May 2026
- 553 Pages
Global
From €4305EUR$4,799USD£3,680GBP
- Report
- September 2025
- 450 Pages
Global
From €4440EUR$4,950USD£3,796GBP
- Report
- August 2026
- 269 Pages
Global
From €5248EUR$5,850USD£4,486GBP
- Report
- June 2026
- 200 Pages
Global
From €2682EUR$2,990USD£2,293GBP
- Report
- January 2026
- 150 Pages
Global
From €5337EUR$5,950USD£4,563GBP
- Report
- January 2026
- 185 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2026
- 194 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2026
- 195 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2026
- 195 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2026
- 191 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2026
- 185 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2026
- 195 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2026
- 188 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2026
- 197 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2026
- 198 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- October 2025
- 183 Pages
Global
From €3180EUR$3,545USD£2,719GBP
€3534EUR$3,939USD£3,021GBP
- Report
- August 2026
- 383 Pages
Global
From €5248EUR$5,850USD£4,486GBP
- Report
- August 2026
- 172 Pages
Global
From €5248EUR$5,850USD£4,486GBP

The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less Read more